Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 523

1.

Trabectedin Reduces Skeletal Prostate Cancer Tumor Size in Association with Effects on M2 Macrophages and Efferocytosis.

Jones JD, Sinder BP, Paige D, Soki FN, Koh AJ, Thiele S, Shiozawa Y, Hofbauer LC, Daignault S, Roca H, McCauley LK.

Neoplasia. 2019 Feb;21(2):172-184. doi: 10.1016/j.neo.2018.11.003. Epub 2018 Dec 31.

2.

Making the Best of Available Options for Optimal Sarcoma Treatment.

Le Cesne A.

Oncology. 2018;95 Suppl 1:11-20. doi: 10.1159/000494861. Epub 2018 Dec 14. Review.

3.

A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.

Assi T, Kattan J, El Rassy E, Honore C, Dumont S, Mir O, Le Cesne A.

Cancer Treat Rev. 2019 Jan;72:37-44. doi: 10.1016/j.ctrv.2018.11.003. Epub 2018 Nov 15. Review.

PMID:
30468937
4.

CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin.

Esser M, Kloth C, Thaiss WM, Reinert CP, Fritz J, Kopp HG, Horger M.

Eur J Radiol. 2018 Oct;107:175-182. doi: 10.1016/j.ejrad.2018.09.006. Epub 2018 Sep 6.

PMID:
30292263
5.

Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.

Marth C.

Expert Rev Anticancer Ther. 2018 Oct;18(sup1):19-22. doi: 10.1080/14737140.2018.1513793.

PMID:
30223697
6.

Management of relapsed ovarian cancer in routine clinical practice: a case study.

Ray-Coquard I.

Expert Rev Anticancer Ther. 2018 Oct;18(sup1):9-11. doi: 10.1080/14737140.2018.1515630.

PMID:
30223695
7.

Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line.

Colombo N.

Expert Rev Anticancer Ther. 2018 Oct;18(sup1):13-17. doi: 10.1080/14737140.2018.1513792. Review.

PMID:
30223694
8.

Marine drugs for cancer: surfacing biotechnological innovations from the oceans.

Jimenez PC, Wilke DV, Costa-Lotufo LV.

Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e482s. doi: 10.6061/clinics/2018/e482s. Review.

9.

Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model.

Kiyuna T, Tome Y, Murakami T, Kawaguchi K, Igarashi K, Miyake K, Miyake M, Li Y, Nelson SD, Dry SM, Singh AS, Russell TA, Elliott I, Singh SR, Kanaya F, Eilber FC, Hoffman RM.

BMC Cancer. 2018 Aug 20;18(1):840. doi: 10.1186/s12885-018-4703-0.

10.

HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.

Loria R, Laquintana V, Bon G, Trisciuoglio D, Frapolli R, Covello R, Amoreo CA, Ferraresi V, Zoccali C, Novello M, Del Bufalo D, Milella M, Biagini R, D'Incalci M, Falcioni R.

Oncogene. 2018 Nov;37(45):5926-5938. doi: 10.1038/s41388-018-0394-x. Epub 2018 Jul 6.

11.

Macrophages: The Road Less Traveled, Changing Anticancer Therapy.

Guerriero JL.

Trends Mol Med. 2018 May;24(5):472-489. doi: 10.1016/j.molmed.2018.03.006. Epub 2018 Apr 11. Review.

PMID:
29655673
12.

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.

Runnebaum IB, Reichert D, Ringsdorf U, Kuther M, Hesse T, Sehouli J, Wimberger P.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1185-1195. doi: 10.1007/s00432-018-2637-1. Epub 2018 Apr 6.

13.

Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma.

Grisanti S, Cosentini D, Tovazzi V, Bianchi S, Lazzari B, Consoli F, Roca E, Berruti A, Ferrari VD.

Support Care Cancer. 2018 Aug;26(8):2929-2935. doi: 10.1007/s00520-018-4129-x. Epub 2018 Mar 15.

PMID:
29546526
14.

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.

Vincenzi B, Badalamenti G, Armento G, Silletta M, Spalato Ceruso M, Catania G, Napolitano A, Maltese G, Valeri S, Incorvaia L, Santini D, Tonini G.

Oncology. 2018;95(1):1-7. doi: 10.1159/000487266. Epub 2018 Mar 6.

PMID:
29510410
15.

Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.

De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, Bongiovanni A, Pieri F, Casadei R, Riva N, Fausti V, Amadori D, Ibrahim T.

Int J Mol Sci. 2017 Dec 8;18(12). pii: E2662. doi: 10.3390/ijms18122662.

16.

Primary breast angiosarcoma - a single institution experience from a tertiary cancer center in South India.

Lokanatha D, Anand A, Lakshmaiah KC, Govind Babu K, Jacob LA, Suresh Babu MC, Lokesh KN, Rudresha AH, Rajeev LK, Saldanha SC, Giri GV, Koppaka D, Kumar RV.

Breast Dis. 2018;37(3):133-138. doi: 10.3233/BD-170291.

PMID:
29286911
17.

Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?

Pompili L, Leonetti C, Biroccio A, Salvati E.

J Exp Clin Cancer Res. 2017 Dec 22;36(1):189. doi: 10.1186/s13046-017-0657-3. Review.

18.

Treatment of recurrent ovarian cancer.

Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441. Review.

PMID:
29232464
19.

EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives.

Vos M, Sleijfer S.

Eur J Cancer. 2018 Jan;88:87-91. doi: 10.1016/j.ejca.2017.10.020. Epub 2017 Dec 1. Review.

PMID:
29202389
20.

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.

Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L, Poggesi I, de Jong J, Triantos S, Park YC, Knoblauch RE, Parekh TV, Demetri GD, von Mehren M.

Invest New Drugs. 2018 Jun;36(3):476-486. doi: 10.1007/s10637-017-0546-9. Epub 2017 Nov 27.

PMID:
29177975

Supplemental Content

Loading ...
Support Center